 BTIG upgraded Implantable lenses-focused Staar Surgical Company NASDAQ: STAA to Buy from Neutral with a 98 price target. Analyst Ryan Zimmerman believes that the Companys fundamentals will likely improve in 2H of 2022 as U.S. physicians appear more apt to try EVO upon. 